Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer
- PMID: 2254761
Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer
Abstract
A phase I clinical trial of the macrophage activator, muramyl tripeptide-phosphatidylethanolamine has been carried out in 37 patients (47 courses) at doses of 0.01-6.0 mg/m2 intravenously twice weekly for 4 weeks. Activation of peripheral blood monocytes and drug toxicity were used as the parameters to monitor the trial. Toxicity was acute systemic responses of fever, chills, and hypertension without a clear dose response. No major organ-related toxicity was seen. A dose of 4.0 mg/m2 biweekly produced activation of blood monocytes; a dose of 6.0 mg/m2 produced inhibition. There was one complete response of 3 months duration in a patient with renal cell carcinoma with pulmonary metastases. The optimum dose for phase II studies is in the range of 1-4 mg/m2 twice weekly for 4 weeks, a dose that is well tolerated.
Similar articles
-
Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine.Cancer Res. 1989 Aug 15;49(16):4665-70. Cancer Res. 1989. PMID: 2787207
-
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.J Clin Oncol. 1989 Dec;7(12):1915-25. doi: 10.1200/JCO.1989.7.12.1915. J Clin Oncol. 1989. PMID: 2479721
-
Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.Am J Clin Oncol. 1995 Apr;18(2):93-9. doi: 10.1097/00000421-199504000-00001. Am J Clin Oncol. 1995. PMID: 7900714 Clinical Trial.
-
Liposomal MTP-PE.J Pediatr Oncol Nurs. 1994 Oct;11(4):161-3. doi: 10.1177/104345429401100407. J Pediatr Oncol Nurs. 1994. PMID: 7946146 Review. No abstract available.
-
Liposomal MTP-PE: a promising new biologic response modifier.Oncol Nurs Forum. 1995 Jun;22(5):809-16. Oncol Nurs Forum. 1995. PMID: 7675688 Review.
Cited by
-
Mifamurtide for the treatment of nonmetastatic osteosarcoma.Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129. Expert Opin Pharmacother. 2011. PMID: 21226638 Free PMC article. Review.
-
A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.Oncotarget. 2017 Jun 13;8(24):39833-39848. doi: 10.18632/oncotarget.16243. Oncotarget. 2017. PMID: 28418855 Free PMC article. Review.
-
A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.Eur J Clin Pharmacol. 2012 Oct;68(10):1347-55. doi: 10.1007/s00228-012-1262-1. Epub 2012 Mar 30. Eur J Clin Pharmacol. 2012. PMID: 22460239 Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.Br J Clin Pharmacol. 2014 Jun;77(6):998-1010. doi: 10.1111/bcp.12261. Br J Clin Pharmacol. 2014. PMID: 24134216 Free PMC article. Clinical Trial.
-
Therapy of disseminated melanoma by liposome-activated macrophages.World J Surg. 1992 Mar-Apr;16(2):270-6. doi: 10.1007/BF02071531. World J Surg. 1992. PMID: 1561809 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources